- Home
- ASBP vs TOVX Comparison
ASBP vs TOVX Comparison
Compare ASBP & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASBP | TOVX |
|---|---|---|
| Founded | 2021 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.4M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | ASBP | TOVX |
|---|---|---|
| Price | $1.35 | $0.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 614.1K | ★ 6.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.05 | $0.16 |
| 52 Week High | $2.45 | $1.50 |
Technical Indicators
Market Signals| Indicator | ASBP | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 46.39 |
| Support Level | $1.20 | $0.17 |
| Resistance Level | $1.63 | $0.27 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 17.43 | 20.27 |
Price Performance
Historical ComparisonAbout ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.